Dr Reddy's launches insomnia treatment tablets in US after FDA approval

Topics Dr Reddys

Dr Reddy's laboratory

Drug major Dr Reddy's Laboratories on Tuesday said it has launched generic Ramelteon tablets used for treatment of insomnia in the US market.

The company has launched Ramelteon tablets in the str8 mgength of 8 mg after getting approval by the United States Food and Drug Administration (USFDA), Dr Reddy's said in a BSE filing.

The product is a generic version of Takeda Pharmaceutical Company's Rozerem tablets in the same strength, it added.

The Rozerem brand had the US sales of around $91.3 million MAT (moving annual total) for the most recent 12 months ending in May 2019, Dr Reddy's said.

The company's generic 8 mg Ramelteon tablets are available in bottle count sizes of 30, 100 and 1,000, it added.

The tablets are indicated for the treatment of insomnia characterised by difficulty with sleep onset.

Shares of Dr Reddy's Laboratories were trading at Rs 2600 per scrip on the BSE, down 1.21 per cent from its previous close.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel